A patient with recalcitrant oral pemphigus vulgaris successfully treated with a biologic drug- Rituximab
Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease affecting mucous membranes and the skin. Rituximab (RTX), a monoclonal antibody against CD20, has been approved by FDA for the treatment of adults with moderate to severe PV. A 42-year-old Indian woman, previously diagnosed with oral...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Online |
| Iaith: | Saesneg |
| Cyhoeddwyd: |
International Association for Dental Research (Nigeria Division)
2019
|
| Mynediad Ar-lein: | https://ajoh.oauife.edu.ng/index.php/ajoh/article/view/41 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|